Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest

Oncology Reports

Volumn 17, Issue 2, 2007, Pages 377-384

  Li, Yan ^a   Liu, Jing ^a   Tang, Li Jun ^a   Shi, Yi Wu ^a   Ren, Wei ^a   Hu, Wei Xin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; KM3 cell line; Lycorine; Multiple myeloma

Indexed keywords

AMARYLLIDACEAE ALKALOID; ANTINEOPLASTIC AGENT; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYTOCHROME C; LYCORINE; PHENANTHRIDINE DERIVATIVE; PLANT EXTRACT; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MULTIPLE MYELOMA; TUMOR CELL LINE;

AMARYLLIDACEAE ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYTOCHROMES C; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; PHENANTHRIDINES; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33947713387     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.2.377     Document Type: Article

References (50)

1. Attal M, Harousseau JL, Stoppa AM, et al: A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97, 1996. (Pubitemid 26240110)
2. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103: 20-32, 2004. (Pubitemid 38029914)
3. Rajkumar SV and Kyle RA: Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80: 1371-1382, 2005. (Pubitemid 41395971)
4. Kuehl W and Bergsagel P: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187, 2002. (Pubitemid 37328787)
5. Hallek M, Bergsagel P and Anderson K: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3-21, 1998. (Pubitemid 28018724)
6. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF and Melton LJ III: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346: 564-569, 2002. (Pubitemid 34438817)
7. Avet-Loiseau H, Facon T, Daviet A, et al: 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 59: 4546-4550, 1999. (Pubitemid 29428955)
8. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood 99: 1745-1757, 2002. (Pubitemid 34533050)
9. Wu K, Orme L, Shaughnessy J, Bumm K, Barlogie B and Moore M: Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood 101: 4982-4989, 2003. (Pubitemid 36868943)
10. Van De Donk NW, Lokhorst HM and Bloem AC: Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 19: 2177-2185, 2005. (Pubitemid 41741612)
11. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88: 386-401, 1996. (Pubitemid 26240369)
12. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
13. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
14. Tian E and Gazitt Y: The role of P53, Bcl-2 and bax in dexamethasone induced apoptosis in myeloma cell lines. Int J Oncol 8: 719-726, 1996. (Pubitemid 26109939)
15. Hu W-X and Gazitt Y: Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 9: 375-381, 1996. (Pubitemid 26236033)
16. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C and Montegomrey W: Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cell lines. Int J Oncol 13: 839-848, 1998. (Pubitemid 28435362)
17. Liu Q and Gazitt Y: Adenovirus-mediated delivery of p53 results in a substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoietic progenitor cells and normal lymphocytes. Exp Hematol 28: 1354-1362, 2000. (Pubitemid 32012540)
18. Liu Q and Gazitt Y: Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 101: 4105-4114, 2003. (Pubitemid 36857892)
19. Strauss M, Lukas J and Bartek J: Unrestricted cell cycling and cancer. Nat Med 1: 1245-1246, 1995.
20. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
21. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996. (Pubitemid 26099813)
22. Hunter T and Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994. (Pubitemid 24363801)
23. INK4A pathway in multiple myeloma. Leukemia 16: 1844-1851, 2002.
24. Jimenez A, Santos A, Alonso G and Vazquez D: Inhibitors of protein synthesis in eukaryotic cells. Comparative effects of some amaryllidaceae alkaloids. Biochim Biophys Acta 425: 342-348, 1976.
25. Vrijsen R, Vanden Berghe DA, Vlietinck AJ and Boeye A: Lycorine: a eukaryotic termination inhibitor? J Biol Chem 261: 505-507, 1986. (Pubitemid 16161696)
26. Lopez, S, Bastida J, Viladomat F and Codina C: Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci 71: 2521-2529, 2002. (Pubitemid 35247960)
27. Elgorashi EE, Stafford GI and Van Staden J: Acetylcholinesterase enzyme inhibitory effects of amaryllidaceae alkaloids. Planta Med 70: 260-262, 2004. (Pubitemid 38445195)
28. Bilge T, Ilkay O and Jutamad S: Antimalarial activity screening of some alkaloids and the plant extracts from Amaryllidaceae. Phytother Res 17: 1220-1223, 2003.
29. Yui S, Mikami M, Kitahara M and Yamazaki M: The inhibitory effect of lycorine on tumor cell apoptosis induced by polymorphonuclear leukocyte-derived calprotectin. Immunopharmacology 40: 151-162, 1998. (Pubitemid 28439169)
30. Liu J, Hu WX, He LF, Mao Y and Li Y: Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS Lett 578: 245-250, 2004. (Pubitemid 39601789)
31. x expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester. J Biol Chem 273: 26779-26789, 1998.
32. Gazitt Y and Erdos GW: Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 54: 950-956, 1994. (Pubitemid 24085445)
33. Sellins KS and Cohen JJ: Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139: 3199-3206, 1987. (Pubitemid 18021967)
34. Mehmet H: Apoptosis: caspase and a new place to hide. Nature 403: 29-30, 2002.
35. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
36. Reed JC: Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 7: 314-319, 2001.
37. Sawyers C: Targeted cancer therapy. Nature 432: 294-297, 2004.
38. Mitsiades N, Mitsiades CS, Poulaki V, et al: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530, 2002. (Pubitemid 34627223)
39. Pei XY, Dai Y and Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17: 2036-2045, 2003. (Pubitemid 37322135)
40. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC and Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59: 1041-1048, 1999. (Pubitemid 29135964)
41. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
42. Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725-731, 2003. (Pubitemid 37492933)
43. Salvesen GS: Caspases: opening the boxes and interpreting the arrows. Cell Death Differ 9: 3-5, 2002.
44. Salvesen GS and Renatus M: Apoptosome: the seven-spoked death machine. Dev Cell 2: 256-257, 2002. (Pubitemid 34266110)
45. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-367, 1999. (Pubitemid 29241128)
46. Cory S, Huang DC and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003. (Pubitemid 38028528)
47. Hartwell LH and Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629-634, 1989. (Pubitemid 19283354)
48. Agami R and Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102: 55-66, 2000.
49. Ely S, Di Liberto M, Niesvizky R, et al: Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 65: 11345-11353, 2005. (Pubitemid 41821691)
50. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN and Beauchamp RD: Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 57: 169-175, 1997. (Pubitemid 27020348)